Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter G Rose

Showing results (11-20 of 201) with videos related to

Pageof 21
Sort By:
Gynecologic Oncology Reports|July 31, 2024
Prolonged treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencingPeter G Rose
Gynecologic Oncology Reports|December 21, 2023
Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case reportPeter G Rose
The Oncologist|March 29, 2005
Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancerPeter G Rose
Obstetrics and Gynecology|June 8, 2022
Symptoms of Women With High-Risk Early-Stage Ovarian CancerPeter G Rose
Cancer Drug Resistance (Alhambra, Calif.)|July 8, 2022
Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspectivePeter G Rose
Seminars in Oncology Nursing|January 2, 2004
Chemotherapy for newly diagnosed and relapsed advanced ovarian cancerPeter G Rose
Clinical Obstetrics and Gynecology|November 5, 2010
Fertility-preserving surgical procedures for patients with gynecologic malignanciesNabila Rasool, Peter G Rose
Anti-Cancer Drugs|July 23, 2013
Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinomaPeter G Rose, Andres Roma
The Lancet. Oncology|December 3, 2020
Landmark studies of therapeutic vaccination in cervical and ovarian cancersPeter G Rose, Haider Mahdi
Gynecologic Oncology|November 6, 2003
Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxelPeter G Rose, Mary Smrekar
Pageof 21

Showing results (11-20 of 201) with videos related to

Sort By:
Pageof 21
Gynecologic Oncology Reports|July 31, 2024
Prolonged treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencingPeter G Rose
Gynecologic Oncology Reports|December 21, 2023
Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case reportPeter G Rose
The Oncologist|March 29, 2005
Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancerPeter G Rose
Obstetrics and Gynecology|June 8, 2022
Symptoms of Women With High-Risk Early-Stage Ovarian CancerPeter G Rose
Cancer Drug Resistance (Alhambra, Calif.)|July 8, 2022
Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspectivePeter G Rose
Seminars in Oncology Nursing|January 2, 2004
Chemotherapy for newly diagnosed and relapsed advanced ovarian cancerPeter G Rose
Clinical Obstetrics and Gynecology|November 5, 2010
Fertility-preserving surgical procedures for patients with gynecologic malignanciesNabila Rasool, Peter G Rose
Anti-Cancer Drugs|July 23, 2013
Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinomaPeter G Rose, Andres Roma
The Lancet. Oncology|December 3, 2020
Landmark studies of therapeutic vaccination in cervical and ovarian cancersPeter G Rose, Haider Mahdi
Gynecologic Oncology|November 6, 2003
Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxelPeter G Rose, Mary Smrekar
Pageof 21